文献速递胸部肿瘤放疗

有创淋巴结分期对不可手术I期NSCLC SBRT后区域和远处复发的影响

Impact of invasive nodal staging on regional and distant recurrence rates after SBRT for inoperable stage I NSCLC.
PubMed 文献 · Radiother Oncol · 2020-07-03

本研究回顾性分析了651例接受根治性SBRT的T1-2N0 NSCLC患者,其中15.2%在PET/CT基础上接受了有创淋巴结分期(EBUS或纵隔镜)。结果显示,与仅PET/CT相比,增加有创分期并未显著改变2年淋巴结和/或远处控制率(78% vs 75%,p=0.877)或总生存。

要点

  • PET/CT阴性后加做有创淋巴结分期未改善2年区域/远处控制或生存。
  • 有创分期使用率15.2%,与年轻、白人、男性、中央型、鳞癌相关。
  • 研究不质疑对PET/CT可疑或阳性淋巴结行有创分期的价值。

核心结论

  • 在PET/CT判定为淋巴结阴性的早期NSCLC患者中,SBRT前增加有创淋巴结分期未明显改变失败模式或生存。

研究设计与样本

  • 单中心回顾性研究,纳入2005-2016年651例接受根治性SBRT的T1-2N0 NSCLC患者,比较PET/CT联合有创分期(EBUS或纵隔镜)与仅PET/CT两组。

主要发现

  • 有创分期组99例(15.2%),其中EBUS 78例、纵隔镜21例;中位随访19.4个月,中位生存28.5个月。
  • 2年淋巴结和/或远处控制率:仅PET/CT组78%(95% CI 74-82%),联合有创分期组75%(95% CI 65-85%),p=0.877。
  • 多因素分析中有创分期的预测因素包括年龄(OR 1.033,95% CI 1.058-1.010)、白人种族(OR 1.852,95% CI 1.044-3.289)、男性(OR 1.629,95% CI 1.031-2.575)、中央型位置(OR 1.978,95% CI 1.218-3.211)和鳞状细胞组织学(OR 2.564,95% CI 1.243-5.287)。
  • 总生存未因分期方式不同而存在差异。

关键数值与推荐

  • 所有患者接受3-5次SBRT,具体分割方案依据机构指南。
  • PET/CT初始可疑或阳性淋巴结的患者被排除。

临床怎么用

  • 对于PET/CT判定为淋巴结阴性的早期NSCLC患者,SBRT前可考虑省略有创淋巴结分期,因其未改善结局。
  • 对PET/CT显示可疑或阳性淋巴结的患者,有创分期的既定价值不受本研究影响。

局限性

  • 单中心回顾性设计,可能存在选择偏倚。
  • 有创分期组样本量较小(n=99),统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVES: Before definitive stereotactic body radiation therapy (SBRT) for presumably node-negative, early-stage NSCLC, many patients are staged with PET/CT alone. In patients undergoing PET/CT prior to SBRT, the role of invasive nodal staging (INS) with endobronchial ultrasound (EBUS) or mediastinoscopy is uncertain. We sought to characterize the impact of nodal staging modality on outcomes. MATERIALS/METHODS: Patients receiving definitive SBRT for T1-2N0 NSCLC deemed node-negative by either PET/CT plus INS (EBUS or mediastinoscopy) or PET/CT alone were identified. Patients with initially equivocal or positive nodes on PET/CT were excluded from this analysis. All patients received 3-5 fraction SBRT according to institutional guidelines. Control was assessed by at least one follow-up CT in all patients. Multivariable logistic regression (MVA) was performed to identify variables independently associated with use of INS. RESULTS: We identified 651 eligible patients at our institution from 2005-2016. INS was performed in 15.2% of patients (n = 99) with EBUS (n = 78) or mediastinoscopy (n = 21). Median follow-up was 19.4 months (0.2-135.1). Median survival was 28.5 months (0.6-140). Factors predictive of increased likelihood of INS after negative PET/CT on MVA were age (OR for decreasing age 1.033; 95% CI 1.058-1.010), Caucasian race (OR vs. non-white 1.852; 1.044-3.289), male sex (1.629; 1.031-2.575), central location (1.978; 1.218-3.211) and squamous histology (2.564; 1.243-5.287). Nodal and/or distant control at 2 years was similar between PET/CT alone (78%, 95% CI 74-82%) and INS + PET/CT (75%, 95% CI 65-85%) (p = 0.877) as well as on MVA. Overall survival did not differ based on staging modality. CONCLUSIONS: In patients with early-stage NSCLC deemed node-negative by PET/CT, addition of INS did not appreciably alter patterns of failure or survival after definitive SBRT. This study does not question the established value of INS for equivocal or suspicious nodes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kennedy WR, Samson PP, Gabani P, et al. Impact of invasive nodal staging on regional and distant recurrence rates after SBRT for inoperable stage I NSCLC. Radiother Oncol. 2020. PMID: 32622780. doi:10.1016/j.radonc.2020.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。